If 2007 is any indication, Pfizer has a tough road ahead. Profit fell a thumping 58% on sales that were down 8%, dropping the drugmaker 10 spots from last year's most-profitable list.
Pfizer lost several important patents during the year, including one for Norvasc, a blood pressure drug with nearly $5 billion in 2006 sales.
And it doesn't get easier. Around 2010, the drugmaker loses its patent on Lipitor, the successful anti-cholesterol drug.
NEXT: Wells Fargo